Divine Aleru, Microbiome Medicine Research Coordinator

Ospemifene (60 mg/day) significantly reduces dyspareunia and improves vaginal health in postmenopausal women with vulvar and vaginal atrophy. It offers a non-estrogenic treatment option, especially for women who cannot use traditional hormone therapies.

This study examined the systemic and local effects of vaginal dehydroepiandrosterone (DHEA) in postmenopausal women, particularly those with a history of breast or gynecologic cancer. It evaluated the impact of vaginal DHEA on hormone concentrations, markers of bone formation, and vaginal cytology, including pH and maturation index. The study aimed to assess […]

This review underscores the importance of nutrition in managing menopausal symptoms and preventing chronic diseases. It highlights key nutrients such as calcium, vitamin D, and protein and promotes a balanced diet and regular physical activity as integral parts of menopausal health management.

This study reveals that higher levels of physical activity, especially during leisure time, are linked to reduced severity of menopausal symptoms, particularly urogenital and somato-vegetative issues. It suggests incorporating physical activity into the management plan for menopausal women, particularly postmenopausal women.

This review and meta-analysis demonstrate that psychological interventions, such as CBT, MBT, and BT, can significantly reduce hot flash bother and menopausal symptoms. These findings are especially relevant for breast cancer survivors, offering a safe, non-hormonal alternative to HRT.

Veozah (fezolinetant) is an effective non-hormonal treatment for menopause-related vasomotor symptoms. It works by targeting the neurokinin 3 receptor and offers a promising alternative to estrogen therapy with minimal side effects, making it suitable for women with contraindications to hormone treatments.

This study demonstrates that gabapentin 300 mg/day is as effective as estrogen 0.625 mg/day for reducing hot flashes in post-menopausal women. It provides a viable non-hormonal alternative with fewer side effects, making it a good option for women unable or unwilling to take estrogen.

This review confirms that SSRIs and SNRIs, particularly paroxetine and venlafaxine, are effective for managing hot flashes in menopausal women. These therapies provide an alternative to hormone replacement therapy, with minimal side effects and considerations for women with specific health concerns, like hypertension or a history of breast cancer.

This review assesses the safety of vaginal hormones and SERMs in treating genitourinary menopausal symptoms in breast cancer survivors. It finds no significant rise in serum estrogen levels or an increased risk of breast cancer recurrence, but more extensive studies are needed to confirm these findings.

This review highlights the lack of conclusive evidence on the safety of hormone replacement therapy (HRT) in women treated for early-stage endometrial cancer. While a small study found no significant increase in cancer recurrence risk, the low quality of the evidence leaves uncertainty about the benefits and risks of HRT use in these women.

This study shows that menopausal hormone therapy increases the risk of gallstones, especially with topical estrogen and tibolone. However, no increased risk for gallbladder cancer was found. These findings underscore the need for caution in prescribing hormone therapy, particularly for women with higher gallstone risk factors.

Long-term use of estrogen and estrogen-progestin therapies significantly increases the risk of endometrial cancer, particularly for women with lower BMI. The risk is dose-dependent, with continuous-combined therapy having complex effects based on body weight.

This review offers updated guidance on the use of menopausal hormone therapy, highlighting its benefits when started early, particularly for women with low cardiovascular risk. It stresses the importance of individualized care and decision-making when considering HT for managing menopausal symptoms.

This review investigates the stroke risk associated with hormonal therapies in postmenopausal women, comparing oral and transdermal estrogen formulations and highlighting the need for individualized treatment plans based on age and cardiovascular health.

This review explores the thrombosis risks of hormonal therapies, comparing various estrogen formulations and progestins. It emphasizes the need for personalized treatment based on thrombophilic risk factors, highlighting the safer options such as transdermal estrogen and progestin-only therapies.

This study explores estrogen’s effects on thrombosis risk in hormonal contraceptives and HRT, highlighting mechanisms of action, the role of different estrogen doses, and the importance of individualized risk assessments in preventing thromboembolic events.

This study examines estrogen’s dual role in breast cancer, focusing on its effects on estrogen receptor-positive cancers and how different therapies, such as SERMs and aromatase inhibitors, mitigate risks while highlighting estrogen metabolism’s role in cancer risk.

The study emphasizes the risks and benefits of menopausal hormone therapy in managing vasomotor symptoms, osteoporosis, and cardiovascular health. It highlights the importance of timing, formulation, and route of administration in optimizing therapy for individual patients.

This review emphasizes the benefits and risks of MHT in managing menopause symptoms, including the prevention of long-term conditions. It advocates for individualized treatment plans, especially focusing on the timing of initiation.

This guideline on menopausal symptom treatment prioritizes early initiation of hormone therapy, safe routes like transdermal estradiol, and vaginal care for genitourinary symptoms. It promotes a tailored approach considering cardiovascular and breast cancer risks.

The review defines menopause vasomotor symptoms treatment and microbiome relevance, favors timely hormone therapy and transdermal routes, details effective nonhormone options, and highlights neurokinin antagonists for fast relief while separating vasomotor and genitourinary care for microbiome-aware practice.

This review sets a simple plan for menopausal hormone therapy first-line management, favors transdermal routes when risk exists, and backs local therapy for genitourinary symptoms with clear links to vaginal ecosystem health.

The review shows that menopausal hormone therapy osteoporosis prevention lowers fractures when started near menopause, favors transdermal routes for safety, and maps RANKL–OPG and cytokine shifts with clear microbiome relevance despite no direct microbiota data.

The guideline links menopausal hormone therapy guidelines and vaginal microbiome care to safer symptom control, better GSM outcomes, and lower UTI risk through local estrogen, with timing and route choices that manage vascular and endometrial risk.